These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 33836725)

  • 1. Under consent: participation of people with HIV in an Ebola vaccine trial in Canada.
    David PM; Mathiot B; Thiongane O; Graham JE
    BMC Med Ethics; 2021 Apr; 22(1):42. PubMed ID: 33836725
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Motivation for participating in phase 1 vaccine trials: Comparison of an influenza and an Ebola randomized controlled trial.
    Cattapan A; Browne K; Halperin DM; Di Castri A; Fullsack P; Graham J; Langley JM; Taylor BA; McNeil SA; Halperin SA
    Vaccine; 2019 Jan; 37(2):289-295. PubMed ID: 30528592
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Factors influencing participation in an Ebola vaccine trial among front-line workers in Guinea.
    Grantz KH; Claudot P; Kambala M; Kouyaté M; Soumah A; Boum Y; Juan-Giner A; Jemmy JP; Cummings DAT; Grais RF
    Vaccine; 2019 Nov; 37(48):7165-7170. PubMed ID: 31623917
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety and immunogenicity of a highly attenuated rVSVN4CT1-EBOVGP1 Ebola virus vaccine: a randomised, double-blind, placebo-controlled, phase 1 clinical trial.
    Clarke DK; Xu R; Matassov D; Latham TE; Ota-Setlik A; Gerardi CS; Luckay A; Witko SE; Hermida L; Higgins T; Tremblay M; Sciotto-Brown S; Chen T; Egan MA; Rusnak JM; Ward LA; Eldridge JH
    Lancet Infect Dis; 2020 Apr; 20(4):455-466. PubMed ID: 31952923
    [TBL] [Abstract][Full Text] [Related]  

  • 5. "We are the heroes because we are ready to die for this country": Participants' decision-making and grounded ethics in an Ebola vaccine clinical trial.
    Tengbeh AF; Enria L; Smout E; Mooney T; Callaghan M; Ishola D; Leigh B; Watson-Jones D; Greenwood B; Larson H; Lees S
    Soc Sci Med; 2018 Apr; 203():35-42. PubMed ID: 29544144
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Enrolling study personnel in Ebola vaccine trials: from guidelines to practice in a non-epidemic context.
    Lhomme E; Modet C; Augier A; Faye S; Dabakuyo-Yonli TS; Levy-Marchal C; D'Ortenzio E; Yazdanpanah Y; Chêne G; Beavogui AH; Richert L;
    Trials; 2019 Jul; 20(1):422. PubMed ID: 31296253
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Participant views and experiences of participating in HIV research in sub-Saharan Africa: a qualitative systematic review.
    Nalubega S; Evans C
    JBI Database System Rev Implement Rep; 2015 Jun; 13(5):330-420. PubMed ID: 26455613
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety and immunogenicity of a two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen in adults in Europe (EBOVAC2): a randomised, observer-blind, participant-blind, placebo-controlled, phase 2 trial.
    Pollard AJ; Launay O; Lelievre JD; Lacabaratz C; Grande S; Goldstein N; Robinson C; Gaddah A; Bockstal V; Wiedemann A; Leyssen M; Luhn K; Richert L; Bétard C; Gibani MM; Clutterbuck EA; Snape MD; Levy Y; Douoguih M; Thiebaut R;
    Lancet Infect Dis; 2021 Apr; 21(4):493-506. PubMed ID: 33217361
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Contextualizing willingness to participate: recommendations for engagement, recruitment & enrolment of Kenyan MSM in future HIV prevention trials.
    Doshi M; Avery L; Kaddu RP; Gichuhi M; Gakii G; du Plessis E; Dutta S; Khan S; Kimani J; Lorway RR
    BMC Public Health; 2017 May; 17(1):469. PubMed ID: 28521748
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Longitudinal assessment of an Ebola vaccine trial understanding among healthcare providers in the Democratic Republic of the Congo.
    Zola Matuvanga T; Larivière Y; Lemey G; Isekah Osang'ir B; Mariën J; Milolo S; Meta R; Matangila J; Maketa V; Mitashi P; Van Geertruyden JP; Muhindo-Mavoko H; Van Damme P
    Vaccine; 2024 Jan; 42(3):481-488. PubMed ID: 38163747
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Behavioral and social science research to support development of educational materials for clinical trials of broadly neutralizing antibodies for HIV treatment and prevention.
    Valente PK; Wu Y; Cohen YZ; Caskey M; Meyers K
    Clin Trials; 2021 Feb; 18(1):17-27. PubMed ID: 32838558
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunity duration of a recombinant adenovirus type-5 vector-based Ebola vaccine and a homologous prime-boost immunisation in healthy adults in China: final report of a randomised, double-blind, placebo-controlled, phase 1 trial.
    Li JX; Hou LH; Meng FY; Wu SP; Hu YM; Liang Q; Chu K; Zhang Z; Xu JJ; Tang R; Wang WJ; Liu P; Hu JL; Luo L; Jiang R; Zhu FC; Chen W
    Lancet Glob Health; 2017 Mar; 5(3):e324-e334. PubMed ID: 28017642
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Perceptions and acceptability of an experimental Ebola vaccine among health care workers, frontline staff, and the general public during the 2014-2015 Ebola outbreak in Sierra Leone.
    Jalloh MF; Jalloh MB; Albert A; Wolff B; Callis A; Ramakrishnan A; Cramer E; Sengeh P; Pratt SA; Conteh L; Hajjeh R; Bunnell R; Redd JT; Ekström AM; Nordenstedt H
    Vaccine; 2019 Mar; 37(11):1495-1502. PubMed ID: 30755367
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Perceptions, attitudes, and willingness of healthcare and frontline workers to participate in an Ebola vaccine trial in Uganda.
    Kimbugwe G; Vatrinet R; Mwanga JA; Kakuru R; Mpeirwe D; Logoose S; Opio K; Kambale M; Seeley J; Grais RF; Marquer C; Kaleebu P; Ssali A
    Vaccine; 2024 Apr; 42(12):3002-3008. PubMed ID: 38565464
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comprehension of informed consent and voluntary participation in registration cohorts for phase IIb HIV vaccine trial in Dar Es Salaam, Tanzania: a qualitative descriptive study.
    Iseselo MK; Tarimo EAM
    BMC Med Ethics; 2024 Mar; 25(1):29. PubMed ID: 38481301
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety and immunogenicity of a recombinant adenovirus type-5 vector-based Ebola vaccine in healthy adults in Sierra Leone: a single-centre, randomised, double-blind, placebo-controlled, phase 2 trial.
    Zhu FC; Wurie AH; Hou LH; Liang Q; Li YH; Russell JB; Wu SP; Li JX; Hu YM; Guo Q; Xu WB; Wurie AR; Wang WJ; Zhang Z; Yin WJ; Ghazzawi M; Zhang X; Duan L; Wang JZ; Chen W
    Lancet; 2017 Feb; 389(10069):621-628. PubMed ID: 28017399
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Accessing health services through the back door: a qualitative interview study investigating reasons why people participate in health research in Canada.
    Townsend A; Cox SM
    BMC Med Ethics; 2013 Oct; 14():40. PubMed ID: 24119203
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Motivation, recruitment, and screening of volunteers for a phase I/II HIV preventive vaccine trial in Thailand.
    Jenkins RA; Chinaworapong S; Morgan PA; Ruangyuttikarn C; Sontirat A; Chiu J; Michael RA; Nitayaphan S; Khamboonruang C
    J Acquir Immune Defic Syndr Hum Retrovirol; 1998 Jun; 18(2):171-7. PubMed ID: 9637582
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Gender aspects on HIV prevention efforts and participation in HIV vaccine trials among Police officers in Dar es Salaam, Tanzania.
    Tarimo EAM; Kakoko DCV; Kohi TW; Bakari M; Sandstrom E; Siyame D; Mhalu F; Kulane A
    BMC Public Health; 2018 Jul; 18(1):905. PubMed ID: 30031376
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Using surrogate vaccines to assess feasibility and acceptability of future HIV vaccine trials in men: a randomised trial in inner-city Johannesburg, South Africa.
    Chimoyi L; Kamndaya M; Venables E; von Knorring N; Stadler J; MacPhail C; Chersich MF; Rees H; Delany-Moretlwe S
    BMC Public Health; 2017 Jul; 17(Suppl 3):524. PubMed ID: 28832280
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.